This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Time to Buy Moderna-Heavy ETFs on Vaccine Optimism?
by Sanghamitra Saha
Shares of Moderna witnessed a significant increase of more than 13% on Jan 2, 2024, driven by Oppenheimer's decision to upgrade the stock to "outperform," as quoted on CNBC.
Biotech ETFs in Focus on Covid Vaccines' Fall Rollout
by Sanghamitra Saha
The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.
Here's Why COVID-Themed ETFs May Come Back Under the Radar
by Sanghamitra Saha
COVID-themed stocks and ETFs were winners in 2020 and some parts of 2021 due to a spike in global coronavirus cases. We may see the same trend again as new COVID variants are 'pretty troublesome.'
Pharma & Biotech ETFs at One-Month High: Here's Why
by Sanghamitra Saha
Pharma and biotech ETFs are in great shape and are trading at a one-month high level.
Moderna ETFs Rallying on COVID-19 Vaccine Booster Shot Update
by Sweta Jaiswal, FRM
Moderna has been rallying on the latest positive booster shot-related update.
Biotech ETFs That Outperformed Last Week
by Sweta Killa
Biotech ETFs was the biggest gainer last week.
Healthcare Emerges as Best Sector of Last Week: 5 Top ETFs
by Sanghamitra Saha
Wall Street was downbeat last week with all indexes in the red. Still, Healthcare sector emerged as a key winner last week.
5 Best Sector ETFs of November
by Sweta Killa
Though the broad markets ended the month in red, a few sector ETFs performed remarkably well.
Moderna ETFs Rallying on COVID-19 Vaccine News to Combat Omicron
by Sweta Jaiswal, FRM
Moderna has been rallying amid concerns surrounding the omicron variant, which has led to possibilities of a rise in demand for COVID-19 vaccines and boosters.
Bet On COVID-Themed ETFs as New Cases Rise Globally
by Sweta Jaiswal, FRM
The remainder of 2021 is expected to continue reeling under the spurt in coronavirus cases. Thus, a COVID-themed ETF could be a wise choice.
Moderna ETFs to Rally on Positive COVID-19 Booster Shot News
by Sweta Jaiswal, FRM
Moderna is expected to gain approval for booster shots for its COVID-19 vaccine.
7 Best ETFs of the First Nine Months of 2021
by Sweta Killa
We highlight seven ETFs from different segments that have outperformed and gained more than 40% in the first nine months of 2021.
Moderna ETFs to Rally on Two-in-One Vaccine Booster Shot News
by Sweta Jaiswal, FRM
Moderna is expected to gain on approval for booster shots and new positive data on its COVID-19 vaccine.
Play COVID-Themed ETFs as US Labor Day Sees Rise in New Cases
by Sweta Jaiswal, FRM
The remainder of 2021 is expected to continue reeling under the spurt in coronavirus cases. Thus, a COVID-themed ETF could be a wise choice.
Healthcare ETFs to Gain on $65-Billion Pandemic Protection Plan
by Sanghamitra Saha
The Biden administration recently offered a $65 billion plan that U.S. officials say is aimed at combating the biological threats after the COVID-19 pandemic goes away.
6 Best ETF Areas of August
by Sanghamitra Saha
Optimism about corporate earnings, U.S. FDA's full approval of Pfizer-BioNTech Covid-19 vaccine, some upbeat economic data points and the passage of the infrastructure bill helped key U.S. equity indexes go higher in August.
5 Must-Watch ETF Charts of Q2 Earnings
by Sweta Killa
Below are five ETFs that have gained from strong earnings results.
ETFs to Buy on Most-Bullish Wall Street Outlook in Two Decades
by Sweta Killa
Wall Street analysts are bullish on stocks in almost two decades with about 56% of all recommendations on S&P 500 firms listed as buys, the highest since 2002.
Moderna ETFs to Shine Bright on Booster Update, New Study Data
by Sweta Jaiswal, FRM
Moderna is expected to gain on approval for booster shots and new positive data on its COVID-19 vaccine.
Best ETF Areas of Last Week
by Sanghamitra Saha
The S&P 500, the Dow Jones and the Nasdaq gained about 0.94%, 0.78% and 1.11% last week.
Are COVID-Themed ETFs Back in Focus as Delta Variant Fears Rise?
by Sweta Jaiswal, FRM
The rest of 2021 is expected to continue bearing the brunt of the coronavirus outbreak. Thus, a COVID-themed ETF could be a smart pick.
Moderna Soars on Inclusion to S&P 500: ETFs in Focus
by Sanghamitra Saha
Moderna, known for its success in the COVID-19 vaccine, has entered the big league with its addition to the S&P 500 Index.
Moderna ETFs to Rise on Positive COVID-19 Vaccine Updates
by Sweta Jaiswal, FRM
Moderna has once again come up with interesting updates about its COVID-19 vaccine.
ETFs to Win as Moderna Seeks COVID-19 Vaccine Nod for Teens
by Sweta Jaiswal, FRM
Moderna (MRNA) is once again in the spotlight with an impressive update relating to mRNA-1273.
5 Sector ETFs That Crushed the Market in April
by Sweta Killa
April proved to be the solid month for the U.S. stock market with all the three major indices hovering near record highs.